BioCardia, Inc. Accounts Receivable
BioCardia, Inc. (BCDA) had Accounts Receivable of $30.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $30.00K.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $20.00K.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $20.00K.
- 2025-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $10.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $30.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $20.00K 10-Q · filed 2026-08-12 | |
| 2025-06-30 | $10.00K 10-Q/A · filed 2025-10-29 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-24 | |
| 2024-09-30 | $10.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $10.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $58.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $63.00K 10-K · filed 2025-03-26 | |
| 2023-09-30 | $104.00K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $115.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $153.00K 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $201.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $300.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $211.00K 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $326.00K 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $147.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $198.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $229.00K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $190.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $232.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $304.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $214.00K 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $179.00K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $147.00K 10-K · filed 2021-03-30 | |
| 2019-09-30 | $103.00K 10-Q · filed 2019-11-19 | |
| 2019-06-30 | $204.00K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $287.00K 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $274.00K 10-K · filed 2020-04-09 | |
| 2018-09-30 | $170.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $191.00K 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $127.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $95.00K 10-K · filed 2019-04-02 | |
| 2017-09-30 | $90.00K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $142.00K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $121.00K 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $74.00K 10-K · filed 2018-03-16 | |
| 2016-06-30 | $142.00K 10-Q · filed 2016-08-02 | |
| 2015-12-31 | $107.00K 10-K · filed 2017-03-30 | $0.00 10-Q · filed 2016-08-02 |
| 2012-12-31 | $0.00 10-K · filed 2013-03-22 | |
| 2012-09-30 | $24.00K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $24.00K 10-Q · filed 2012-08-10 | |
| 2012-03-31 | $24.00K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $67.00K 10-K · filed 2013-03-22 | |
| 2011-09-30 | $140.00K 10-Q · filed 2011-11-15 | |
| 2011-06-30 | $267.00K 10-Q/A · filed 2011-11-17 | |
| 2010-12-31 | $413.00K 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |